Phase II trial of the phosphatidyinositol-3 kinase (PLIK) inhibitor buparlisib (BKM120) in recurrent glioblastoma

被引：4
|
作者：
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Ramkissoon, Shakti
Alexander, Brian Michael
Rinne, Mikael L.
Colman, Howard
Omura, Antonio MarcIllo Paduia
DeAngelis, Lisa Marie
Gilbert, Mark R.
De Groot, John Frederick
Cloughesy, Timothy Francis
Chi, Andrew S.
Lee, Eudocia Quant
Nayak, Lakshmi
Batchelor, Tracy
Chang, Susan Marina
Prados, Michael
Reardon, David A.
Ligon, Keith L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM)
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Mellinghoff, Ingo K.
    Lamborn, Kathleen
    Ramkissoon, Shakti
    Cloughesy, Timothy Francis
    Rinne, Mikael
    Omuro, Antonio Marcilio Padula
    DeAngelis, Lisa Marie
    Gilbert, Mark R.
    Chi, Andrew S.
    Batchelor, Tracy
    Colman, Howard
    Chang, Susan Marina
    Massacesi, Cristian
    DiTomaso, Emmanuelle
    Prados, Michael
    Reardon, David A.
    Ligon, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA: AN IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM STUDY
    Wen, Patrick
    Yung, Alfred
    Mellinghoff, Ingo
    Lamborn, Kathleen
    Ramkissoon, Shakti
    Cloughesy, Timothy
    Rinne, Mikael
    Omuro, Antonio
    DeAngelis, Lisa
    Gilbert, Mark
    Chi, Andrew
    Batchelor, Tracy
    Colman, Howard
    Chang, Susan
    Nayak, Lakshmi
    Massacesi, Cristian
    DiTomaso, Emmanuelle
    Prados, Michael
    Reardon, David
    Ligon, Keith
    NEURO-ONCOLOGY, 2013, 15 : 134 - 134
  • [3] PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM
    Wen, Patrick Y.
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Mellinghoff, Ingo K.
    Ramkissoon, Shakti
    Alexander, Brian
    Rinne, Mikael
    Colman, Howard
    Omuro, Antonio M.
    DeAngelis, Lisa M.
    Gilbert, Mark R.
    DeGroot, John
    Cloughesy, Timothy F.
    Lee, Eudocia Q.
    Nayak, Lakshmi
    Chi, Andrew S.
    Batchelor, Tracy
    Chang, Susan M.
    Prados, Michael D.
    Reardon, David A.
    Ligon, Keith L.
    NEURO-ONCOLOGY, 2014, 16
  • [4] A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas.
    Abu Zaid, Mohammad Issam
    Radovich, Milan
    Althouse, Sandra K.
    Liu, Hai
    Spittler, Aaron John
    Solzak, Jeffrey Peter
    Hancock, Bradley Allen
    Loehrer, Patrick J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM).
    Shih, Kent C.
    Chowdhary, Sajeel A.
    Becker, Kevin P.
    Baehring, Joachim M.
    Liggett, William H.
    Burris, Howard A.
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
    Martin van den Bent
    Analia Azaro
    Filip De Vos
    Juan Sepulveda
    W. K. Alfred Yung
    Patrick Y. Wen
    Andrew B. Lassman
    Markus Joerger
    Ghazaleh Tabatabai
    Jordi Rodon
    Ralph Tiedt
    Sylvia Zhao
    Tiina Kirsilae
    Yi Cheng
    Sergio Vicente
    O. Alejandro Balbin
    Hefei Zhang
    Wolfgang Wick
    Journal of Neuro-Oncology, 2020, 146 : 79 - 89
  • [7] A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA
    van den Bent, Martin
    Azaro, Analia
    Vos, Filip
    Sepulveda, Juan
    Yung, W. K. Alfred
    Wen, Patrick
    Lassman, Andrew
    Joerger, Markus
    Tabatabai, Ghazaleh
    Rodon, Jordi
    Tiedt, Ralph
    Zhao, Sylvia
    Kirsilae, Tiina
    Vicente, Sergio
    Myers, Andrea
    Wick, Wolfgang
    NEURO-ONCOLOGY, 2017, 19 : 16 - 17
  • [8] BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
    Speranza, Maria-Carmela
    Nowicki, Michal O.
    Behera, Prajna
    Cho, Choi-Fong
    Chiocca, E. Antonio
    Lawler, Sean E.
    SCIENTIFIC REPORTS, 2016, 6
  • [9] A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
    van den Bent, Martin
    Azaro, Analia
    De Vos, Filip
    Sepulveda, Juan
    Yung, W. K. Alfred
    Wen, Patrick Y.
    Lassman, Andrew B.
    Joerger, Markus
    Tabatabai, Ghazaleh
    Rodon, Jordi
    Tiedt, Ralph
    Zhao, Sylvia
    Kirsilae, Tiina
    Cheng, Yi
    Vicente, Sergio
    Balbin, O. Alejandro
    Zhang, Hefei
    Wick, Wolfgang
    JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (01) : 79 - 89
  • [10] BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
    Maria-Carmela Speranza
    Michal O. Nowicki
    Prajna Behera
    Choi-Fong Cho
    E. Antonio Chiocca
    Sean E. Lawler
    Scientific Reports, 6
12345